Health & Life Co., Ltd.

As of June 30, 2026, Health & Life Co., Ltd. carries a market capitalization of 559.41M, placing it among publicly traded companies globally. Its enterprise value stands at 535.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Health & Life Co., Ltd. has 47.41M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.39, and the price-to-book ratio stands at 1.84.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 535.03M versus a market cap of 559.41M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Health & Life Co., Ltd. maintains a current ratio of 2.71, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.31, indicating elevated leverage, while an interest coverage ratio of -10.55 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Health & Life Co., Ltd. posted a negative return on equity (ROE) of -15.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.58, reflecting losses generated across the asset base. The company generates approximately 2.56M in revenue per employee across its workforce of 156.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.16 indicates how many times Health & Life Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Health & Life Co., Ltd. recorded 1.74M in income tax expense. The company reported a pretax loss of -48.93M and -50.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Health & Life Co., Ltd.'s stock has declined approximately 22.24% over the past 52 weeks. The 50-day moving average sits at 10.33, while the 200-day moving average is 11.39.

Over the twelve months ended June 30, 2026, Health & Life Co., Ltd. generated 400.09M in revenue and converted that into -50.67M in net income, yielding earnings per share of -1.07. EBITDA reached -61.06M, while operating income came in at -75.04M.

As of June 30, 2026, Health & Life Co., Ltd. holds 222.42M in cash and equivalents against 198.03M in total debt, resulting in a net debt position of -29.20M. Total book value stands at 303.23M, with working capital of 265.90M providing operational flexibility.

Health & Life Co., Ltd. produced -16.59M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -8.79M in capital expenditures, free cash flow totaled -25.38M - equivalent to -0.54 per share.

Over the twelve months ended June 30, 2026, Health & Life Co., Ltd. posted a gross margin of 13.72, reflecting its pricing power and cost economics. The operating margin of -18.76 and net profit margin of -12.66 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.56: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 2.81, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Health & Life Co., Ltd. shareholders.

Health & Life Co., Ltd.'s most recent stock split took place on September 14, 2006 with a 414:427 split ratio.

As of June 30, 2026, Health & Life Co., Ltd. has an Altman Z-Score of 1.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.